Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors : A narrative review of head-to-head comparisons. / Dalsgaard, Niels B; Vilsbøll, Tina; Knop, Filip K.

I: Diabetes, Obesity and Metabolism, Bind 20, Nr. 3, 03.2018, s. 508-519.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Dalsgaard, NB, Vilsbøll, T & Knop, FK 2018, 'Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons', Diabetes, Obesity and Metabolism, bind 20, nr. 3, s. 508-519. https://doi.org/10.1111/dom.13128

APA

Dalsgaard, N. B., Vilsbøll, T., & Knop, F. K. (2018). Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. Diabetes, Obesity and Metabolism, 20(3), 508-519. https://doi.org/10.1111/dom.13128

Vancouver

Dalsgaard NB, Vilsbøll T, Knop FK. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. Diabetes, Obesity and Metabolism. 2018 mar;20(3):508-519. https://doi.org/10.1111/dom.13128

Author

Dalsgaard, Niels B ; Vilsbøll, Tina ; Knop, Filip K. / Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors : A narrative review of head-to-head comparisons. I: Diabetes, Obesity and Metabolism. 2018 ; Bind 20, Nr. 3. s. 508-519.

Bibtex

@article{c2bcd32464564b7994361d7213949a96,
title = "Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons",
abstract = "Cardiovascular (CV) disease is the leading cause of death and morbidity in patients with type 2 diabetes. Five CV risk factors (blood pressure, resting heart rate, body weight, cholesterol levels and blood glucose) are monitored routinely as safety and efficacy endpoints in randomized clinical trials for diabetes therapies. To determine if different glucagon-like peptide-1 receptor agonists (GLP-1RAs) had varying effects on these CV risk factors, we reviewed 16 head-to-head trials directly comparing GLP-1RAs that included at least one of the five factors. Few trials reported statistical differences between GLP-1RAs in terms of systolic blood pressure (SBP), body weight and total cholesterol. Liraglutide increased heart rate vs its comparators in three separate trials. All GLP-1RAs reduced glycated haemoglobin (HbA1c), but exenatide twice daily and lixisenatide had statistically smaller effects compared with other GLP-1RAs. These descriptive data indicate that individual GLP-1RAs affect CV risk factors differently, potentially because of their individual pharmacokinetics and/or size. Short-acting GLP-1RAs appeared to result in smaller changes in SBP and total cholesterol compared with continuous-acting treatments, while large GLP-1RAs had a reduced effect on body weight compared with small GLP-1RAs. For glycaemic control, short-acting GLP-1RAs had a greater impact on postprandial glucose levels vs continuous-acting GLP-1RAs, but for fasting plasma glucose levels and HbA1c, continuous-acting treatments had the greater effect. No differentiating trends were obvious in heart rate data. These diverse actions of GLP-1RAs on CV risk factors should aid individualized patient treatment.",
keywords = "Journal Article, Review",
author = "Dalsgaard, {Niels B} and Tina Vilsb{\o}ll and Knop, {Filip K}",
note = "{\circledC} 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.",
year = "2018",
month = "3",
doi = "10.1111/dom.13128",
language = "English",
volume = "20",
pages = "508--519",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors

T2 - A narrative review of head-to-head comparisons

AU - Dalsgaard, Niels B

AU - Vilsbøll, Tina

AU - Knop, Filip K

N1 - © 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

PY - 2018/3

Y1 - 2018/3

N2 - Cardiovascular (CV) disease is the leading cause of death and morbidity in patients with type 2 diabetes. Five CV risk factors (blood pressure, resting heart rate, body weight, cholesterol levels and blood glucose) are monitored routinely as safety and efficacy endpoints in randomized clinical trials for diabetes therapies. To determine if different glucagon-like peptide-1 receptor agonists (GLP-1RAs) had varying effects on these CV risk factors, we reviewed 16 head-to-head trials directly comparing GLP-1RAs that included at least one of the five factors. Few trials reported statistical differences between GLP-1RAs in terms of systolic blood pressure (SBP), body weight and total cholesterol. Liraglutide increased heart rate vs its comparators in three separate trials. All GLP-1RAs reduced glycated haemoglobin (HbA1c), but exenatide twice daily and lixisenatide had statistically smaller effects compared with other GLP-1RAs. These descriptive data indicate that individual GLP-1RAs affect CV risk factors differently, potentially because of their individual pharmacokinetics and/or size. Short-acting GLP-1RAs appeared to result in smaller changes in SBP and total cholesterol compared with continuous-acting treatments, while large GLP-1RAs had a reduced effect on body weight compared with small GLP-1RAs. For glycaemic control, short-acting GLP-1RAs had a greater impact on postprandial glucose levels vs continuous-acting GLP-1RAs, but for fasting plasma glucose levels and HbA1c, continuous-acting treatments had the greater effect. No differentiating trends were obvious in heart rate data. These diverse actions of GLP-1RAs on CV risk factors should aid individualized patient treatment.

AB - Cardiovascular (CV) disease is the leading cause of death and morbidity in patients with type 2 diabetes. Five CV risk factors (blood pressure, resting heart rate, body weight, cholesterol levels and blood glucose) are monitored routinely as safety and efficacy endpoints in randomized clinical trials for diabetes therapies. To determine if different glucagon-like peptide-1 receptor agonists (GLP-1RAs) had varying effects on these CV risk factors, we reviewed 16 head-to-head trials directly comparing GLP-1RAs that included at least one of the five factors. Few trials reported statistical differences between GLP-1RAs in terms of systolic blood pressure (SBP), body weight and total cholesterol. Liraglutide increased heart rate vs its comparators in three separate trials. All GLP-1RAs reduced glycated haemoglobin (HbA1c), but exenatide twice daily and lixisenatide had statistically smaller effects compared with other GLP-1RAs. These descriptive data indicate that individual GLP-1RAs affect CV risk factors differently, potentially because of their individual pharmacokinetics and/or size. Short-acting GLP-1RAs appeared to result in smaller changes in SBP and total cholesterol compared with continuous-acting treatments, while large GLP-1RAs had a reduced effect on body weight compared with small GLP-1RAs. For glycaemic control, short-acting GLP-1RAs had a greater impact on postprandial glucose levels vs continuous-acting GLP-1RAs, but for fasting plasma glucose levels and HbA1c, continuous-acting treatments had the greater effect. No differentiating trends were obvious in heart rate data. These diverse actions of GLP-1RAs on CV risk factors should aid individualized patient treatment.

KW - Journal Article

KW - Review

U2 - 10.1111/dom.13128

DO - 10.1111/dom.13128

M3 - Review

C2 - 29024408

VL - 20

SP - 508

EP - 519

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 3

ER -

ID: 186413734